Eiger chalks up one win, one loss be­tween a pair of PhII rare dis­ease drugs, reshuf­fling pri­or­i­ties

Months af­ter Eiger Bio­phar­ma­ceu­ti­cals con­ced­ed uben­imex had no ef­fect in pul­monary ar­te­r­i­al hy­per­ten­sion, the drug has proven to be a flop again — this time in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.